Evidence map›Paper›PMID 17273184›Full record

ArticleCancer gene therapy2007

Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.

S Goding, Q Yang, Z Mi, P D Robbins, P H Basse

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of CancerTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. NK cells in the tumor microenvironment.Critical reviews in oncogenesis · 2014
    Review
  9. Lentiviral gene transduction in human and mouse NK cell lines.Methods in molecular biology (Clifton, N.J.) · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S GodingDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Q Yang
Z Mi
P D Robbins
P H Basse
UPMC Hillman Cancer Center · USUniversity of Pittsburgh · US

Funding

A New Strategy for Targeted Chemoimmunotherapy of CancerR01CA087672 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BASSE, PER H. · 2002 to 2004
$732k
Cytokine Delivery By Tumor-Seeking LymphocytesR01CA104560 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BASSE, PER H. · 2004 to 2006
$672k
NCI NIH HHS R01CA104560NCI NIH HHS R01CA87672
6 · The paper itself

Abstract

Despite successes in animals, cytokine gene expression selectively in human tumors is difficult to achieve owing to lack of efficient delivery methods. Since interleukin (IL)-2-activated natural killer (A-NK) and phytohemagglutinin and IL-2 activated killer T (T-LAK) cells, as previously demonstrated, localize and accumulate in murine lung tumor metastases following adoptive transfer, we transduced them to test their ability to deliver products of genes selectively to tumors. Assessments of transduction efficiency in vitro demonstrated that adenoviral transduction consistently resulted in high (>60%) transduction rates and substantial expression of transgenes such as GFP, Red2, luciferase, beta-galactosidase and mIL-12 for at least 4 days. In vivo experiments illustrated that Ad-GFP transduced A-NK and Ad-Red2 (RFP) transduced T-LAK or mIL-12 transduced A-NK cells localized 10-50-fold more or survived significantly better than mock transduced cells, respectively, within lung metastases than in the surrounding normal lung tissue. Most importantly, mIL-12 transduced A-NK cells provided a significantly greater antitumor response than non-transduced A-NK cells. Thus, adoptive transfer of A-NK and T-LAK cells represents an efficient method for targeting products of genes to tumor sites.

Indexed as

AdenoviridaeAdoptive TransferAnimalsGalactosidasesGenetic TherapyGreen Fluorescent ProteinsInterleukin-12Killer Cells, Lymphokine-ActivatedKiller Cells, NaturalLuciferasesLung NeoplasmsMiceMice, Inbred StrainsT-Lymphocyte SubsetsTransduction, Geneticenhanced green fluorescent proteinGalactosidasesGreen Fluorescent ProteinsInterleukin-12Luciferases

Identifiers

PMID17273184
OpenAlexW2027636850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.